Loading
Surgeon-scientist who led the first neoadjuvant pembrolizumab trial in head and neck cancer and the KEYNOTE-689 study that made it standard.
Ravindra Uppaluri led the first window-of-opportunity trial of neoadjuvant pembrolizumab in resectable head and neck squamous cell carcinoma, defining pathological response as a marker, and was global principal investigator of KEYNOTE-689, which showed perioperative pembrolizumab improves event-free survival in locally advanced resectable disease, the first new curative-intent approach in two decades. His laboratory studies immune escape in head and neck cancer.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant and adjuvant pembrolizumab in advanced head and neck squamous cell carcinoma (KEYNOTE-689) | NEJM | 2025 |
| Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial | Clinical Cancer Research | 2020 |
Shares Dana-Farber Brigham Cancer Center, PD-1, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag head-and-neck.
Shares KEYNOTE-689, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag head-and-neck.
Shares Dana-Farber Brigham Cancer Center, PD-1, Immune checkpoint inhibitors.
Shares KEYNOTE-689, Pembrolizumab.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, surgery.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, surgery.